Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial. - Wei ZG; Chen HJ; Wang DJ; Jiang Z; Pei YY; Li LY; Wang F; Jin J; Liu ZR; Chen F; Liu J; Peng XC (Nature communications, 2025)